Advertisement
Advertisement
ARQT
Arcutis Biotherapeutics, Inc. Common Stock
25.55
USDSponsored
-1.45
-5.37%
Nov 06, 15:59 UTC -5
Closed
After-Market
25.55
0.00
-0.02%
Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Earnings
ARQT Earnings Reports
Positive Surprise Ratio
ARQT beat 22 of 28 last estimates.
79%
Next Report
Date of Next Report
Feb 23, 2027
Estimate for Q4 26 (Revenue/ EPS)
$163.89M
/$0.24
Implied change from Q3 26 (Revenue/ EPS)
+13.87%
/+300.00%
Implied change from Q4 25 (Revenue/ EPS)
+26.55%
/+84.62%
Arcutis Biotherapeutics, Inc. Common Stock earnings per share and revenue
On Nov 04, 2026, ARQT reported earnings of 0.06 USD per share (EPS) for Q3 26, missing the estimate of 0.16 USD, resulting in a -64.54% surprise. Revenue reached 143.92 million, compared to an expected 145.44 million, with a -1.05% difference. The market reacted with a -20.70% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 5 analysts forecast an EPS of 0.24 USD, with revenue projected to reach 163.89 million USD, implying an increase of 300.00% EPS, and increase of 13.87% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
FAQ
What were Arcutis Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Arcutis Biotherapeutics, Inc. Common Stock reported EPS of $0.06, missing estimates by -64.54%, and revenue of $143.92M, -1.05% below expectations.
How did the market react to Arcutis Biotherapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -20.7%, changed from $34.05 before the earnings release to $27.00 the day after.
When is Arcutis Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 23, 2027.
What are the forecasts for Arcutis Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Arcutis Biotherapeutics, Inc. Common Stock is expected to report EPS of $0.24 and revenue of $163.89M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.